#Japan #Tokyo #CAR-T therapy #Noile Immune #Yamaguchi University

Introduction

Noile Immune Biotech, headquartered in Minato, Tokyo, is excited to announce a collaborative research initiative with Yamaguchi University and Hitachi aimed at improving CAR-T cell therapy technology. This partnership will utilize Noile Immune's proprietary CAR sequences to enhance the design and screening of optimized CAR-T cells, with a significant focus on treating solid tumors.

Key Players in the Research

The research will be led by Noile Immune's CEO Koji Tamada, who also serves as a professor at Yamaguchi University's Graduate School of Medicine in the Immunology department, as well as Director of the Cell Design Institute. Associate professor Yukimi Sakoda, also affiliated with Yamaguchi University's immunology research, will act as an advisor in this initiative. Their combined expertise will ensure rigorous research alongside Hitachi, which will officially commence on December 16, 2025.

The Role of CAR Sequences

At the heart of this collaborative effort lies the CAR (Chimeric Antigen Receptor) sequences provided by Noile Immune. These sequences are critical in enabling CAR-T cells to identify and attack cancer cells effectively. The research aims to enhance the design and functionality of CAR-T cells, thereby increasing their efficacy against solid tumors and potentially improving the safety and effectiveness of treatment pipelines available for cancer patients.

Expectations and Future Prospects

As this research progresses, it is anticipated that Noile Immune's developing PRIME CAR-T will be further optimized. This could lead to significant improvements in clinical outcomes, including increased safety and efficacy of cancer treatments, which in turn may enhance commercialization prospects and overall pipeline value. Noile Immune remains committed to contributing innovative solutions in combating cancer globally, striving to provide patients with new therapeutic options through advanced immunotherapy.

PRIME Technology Overview

PRIME technology, a proprietary innovation from Noile Immune, aims to enhance the efficacy of immune cells, including CAR-T cells. The technology facilitates the production of interleukin-7 (IL-7) and CCL19, promoting T cell proliferation and survival while enhancing their motility alongside dendritic cells. This synergistic effect is designed to create an optimal environment for attacking cancer cells locally, thus maximizing treatment effectiveness.
For more details on PRIME technology, visit Noile Immune's official page.

About Noile Immune Biotech

Noile Immune Biotech (TSE: 4893) is at the forefront of next-generation immunotherapy focusing on solid tumors, leveraging its innovative PRIME technology embedded in its PRIME CAR-T cells. The versatility of PRIME technology allows for new drug creation through various chimeric antigen receptor (CAR) combinations, paving the way for diverse therapeutic modalities. Our commitment is to foster a society where cancer can be conquered. For further information on our initiatives and technology, please visit Noile Immune's website.